Access to Care and Therapy for Kawasaki Disease in the Arab Countries: A Kawasaki Disease Arab Initiative (Kawarabi) Multicenter Survey

Abstract Kawasaki Disease (KD) is still the most common acquired heart disease in children below the age of five years; it has been well described in the developed world; however, data from the Arab world are limited to case reports or single-center case series. In an effort of optimizing KD research in the Arab world, a group of physicians and researchers established the KD Arab Initiative (Kawarabi) in 2021, and published the first survey, which showed disparities in the availability of intravenous immunoglobulin (IVIG); this had prompted Kawarabi to assess the access to care and therapy of KD patients in Arab countries. A 32 structured questions survey was conducted in thirteen Arab countries and addressed KD patients’ access to healthcare in urban and rural settings. The survey results showed that access to care was uniform across large, mid-size cities and rural areas in 7/13 (54%) countries, while in 6/13 (46%) countries, it was in favor of large and mid-size cities over rural areas. The quality of medical services received by children with KD in large cities was rated as excellent in 6/13 or good in 7/13 countries compared to fair in 4/13 or poor in 4/13 countries in rural areas. Availability of IVIG was limited (23%) in mid-size cities and almost impossible (23%) in rural areas. The KD patients in mid-size cities and rural areas have limited access to standard healthcare in the Arab world. This survey laid the foundation for future Kawarabi endeavors to improve the care of children with KD..

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:44

Enthalten in:

Pediatric cardiology - 44(2023), 6 vom: 01. Mai, Seite 1277-1284

Sprache:

Englisch

Beteiligte Personen:

Alzyoud, Raed [VerfasserIn]
El-Kholy, Nermeen [VerfasserIn]
Arab, Yousra [VerfasserIn]
Choueiter, Nadine [VerfasserIn]
Harahsheh, Ashraf S. [VerfasserIn]
Aselan, Adnan Salem [VerfasserIn]
Kotby, Alyaa [VerfasserIn]
Bouaziz, Asma [VerfasserIn]
Salih, Aso F. [VerfasserIn]
Abushhaiwia, Awatif [VerfasserIn]
Alahmadi, Fahad [VerfasserIn]
Agha, Hala M. [VerfasserIn]
Elmarsafawy, Hala M. [VerfasserIn]
Alrabte, Hanifa [VerfasserIn]
Al-Saloos, Hesham [VerfasserIn]
Boudiaf, Houda [VerfasserIn]
Hijazi, Issa [VerfasserIn]
Bouayed, Kenza [VerfasserIn]
Al Senaidi, Khalfan Salim [VerfasserIn]
Boughammoura, Lamia [VerfasserIn]
Jalal, Maryam [VerfasserIn]
Ladj, Mohamed S. [VerfasserIn]
Abu-Shukair, Mohammed E. [VerfasserIn]
ElGanzoury, Mona M. [VerfasserIn]
Hammadouche, Nacera [VerfasserIn]
Elsamman, Nora [VerfasserIn]
Mouawad, Pierre [VerfasserIn]
Boukari, Rachida [VerfasserIn]
Benalikhoudja, Nassiba [VerfasserIn]
Jdour, Salima [VerfasserIn]
Abu Al-Saoud, Sima Y. [VerfasserIn]
Touri, Soued Nabila [VerfasserIn]
Kammoun, Thouraya [VerfasserIn]
Fitouri, Zohra [VerfasserIn]
Dahdah, Nagib [VerfasserIn]

Links:

Volltext [lizenzpflichtig]

Themen:

Arab
Intravenous Immunoglobulins
Kawasaki Disease
Treatment

Anmerkungen:

© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

doi:

10.1007/s00246-023-03166-1

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

SPR052031195